Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06049017 · ClinicalTrials.gov registry record · Phase 2
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 252
- Enrollment target
NCT06049017 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 252 participants.
The verdict
NCT06049017, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 252 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.
Interventions
- DRUG Placebo
- DRUG JNJ-77242113
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2023-10-09 |
| Est. Completion | 2026-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06049017
The ClinicalTrials.gov registry entry for NCT06049017 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06049017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06049017 about?
NCT06049017 is a clinical study titled "A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis". The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.
What is the current status of trial NCT06049017?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 252 participants. The study started on 2023-10-09. Estimated completion is 2026-01-05.
What interventions are being tested in trial NCT06049017?
The interventions under investigation include: Placebo (DRUG), JNJ-77242113 (DRUG).
Who is sponsoring clinical trial NCT06049017?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.